Abstract：
Our review aimed to consolidate the latest update on the application of in vitro maturation among immature oocyte harvest in combination with ovarian tissue cryopreservation known as ovarian tissue oocyte-in vitro maturation.
A thorough search for relevant studies was conducted via PubMed, Google Scholar, EMBASE, and clinical.gov databases up to December 2020. The primary outcome was the oocyte maturation rate, which measured the number of immature oocytes (geminal vesicle stage) that progressed to mature oocytes (meiosis II stage) following in vitro maturation. The secondary outcomes were the fertilization rate following intracytoplasmic sperm injection/in vitro fertilization of these oocytes for the embryo cryopreservation cohort. Our review included pre-pubertal girls and women with cancer who underwent ovarian tissue oocyte-in vitro maturation as fertility preservation.
The primary search identified 207 studies. Twelve manuscripts were selected for inclusion in our review following duplication assessment, title and abstract screening, and full-text evaluation tailored to our inclusion criteria. All the population belonged to a cancer group and underwent concurrent ovarian tissue oocyte-in vitro maturation. A total of 5724 immature oocytes were obtained following ovarian tissue cryopreservation. Approximately 33.84% of the immature oocytes successfully matured via in vitro maturation, which were cryopreserved as oocytes or fertilized as embryos and subsequently stored for future use.
Our review proposed the potential application of ovarian tissue oocyte-in vitro maturation in increasing the number of mature oocytes. The acceptable improvement in oocyte maturation rate following in vitro maturation indicates that improving oocyte outcomes is an excellent cost-effective strategy for fertility preservation among women with cancer.
A thorough search for relevant studies was conducted via PubMed, Google Scholar, EMBASE, and clinical.gov databases up to December 2020. The primary outcome was the oocyte maturation rate, which measured the number of immature oocytes (geminal vesicle stage) that progressed to mature oocytes (meiosis II stage) following in vitro maturation. The secondary outcomes were the fertilization rate following intracytoplasmic sperm injection/in vitro fertilization of these oocytes for the embryo cryopreservation cohort. Our review included pre-pubertal girls and women with cancer who underwent ovarian tissue oocyte-in vitro maturation as fertility preservation.
The primary search identified 207 studies. Twelve manuscripts were selected for inclusion in our review following duplication assessment, title and abstract screening, and full-text evaluation tailored to our inclusion criteria. All the population belonged to a cancer group and underwent concurrent ovarian tissue oocyte-in vitro maturation. A total of 5724 immature oocytes were obtained following ovarian tissue cryopreservation. Approximately 33.84% of the immature oocytes successfully matured via in vitro maturation, which were cryopreserved as oocytes or fertilized as embryos and subsequently stored for future use.
Our review proposed the potential application of ovarian tissue oocyte-in vitro maturation in increasing the number of mature oocytes. The acceptable improvement in oocyte maturation rate following in vitro maturation indicates that improving oocyte outcomes is an excellent cost-effective strategy for fertility preservation among women with cancer.
摘要：
我们的评论旨在巩固有关未成熟卵母细胞收获物中体外成熟与卵巢组织冷冻保存相结合的最新更新，称为卵巢组织卵母细胞体外成熟。
通过PubMed对相关研究进行了彻底的搜索，谷歌学者，EMBASE,以及截至2020年12月的clinical.gov数据库。主要结果是卵母细胞成熟率，它测量了在体外成熟后发展为成熟卵母细胞（减数分裂II期）的未成熟卵母细胞（齿囊阶段）的数量。次要结果是胚胎冷冻保存队列的卵胞浆内单精子注射/体外受精后的受精率。我们的审查包括青春期前女孩和患有癌症的妇女，她们接受了卵巢组织卵母细胞体外成熟作为生育能力保存。
主要搜索确定了207项研究。在重复评估后，我们选择了12份手稿纳入我们的审查，标题和摘要筛选，和适合我们纳入标准的全文评估。所有人群都属于癌症组，并同时经历了卵巢组织卵母细胞体外成熟。卵巢组织冷冻保存后，共获得5724个未成熟卵母细胞。约33.84%的未成熟卵母细胞通过体外成熟成功成熟，冷冻保存为卵母细胞或受精为胚胎，随后储存以备将来使用。
我们的综述提出了卵巢组织卵母细胞体外成熟在增加成熟卵母细胞数量方面的潜在应用。体外成熟后卵母细胞成熟率的可接受改善表明，改善卵母细胞结局是癌症女性保留生育能力的极好的成本效益策略。
通过PubMed对相关研究进行了彻底的搜索，谷歌学者，EMBASE,以及截至2020年12月的clinical.gov数据库。主要结果是卵母细胞成熟率，它测量了在体外成熟后发展为成熟卵母细胞（减数分裂II期）的未成熟卵母细胞（齿囊阶段）的数量。次要结果是胚胎冷冻保存队列的卵胞浆内单精子注射/体外受精后的受精率。我们的审查包括青春期前女孩和患有癌症的妇女，她们接受了卵巢组织卵母细胞体外成熟作为生育能力保存。
主要搜索确定了207项研究。在重复评估后，我们选择了12份手稿纳入我们的审查，标题和摘要筛选，和适合我们纳入标准的全文评估。所有人群都属于癌症组，并同时经历了卵巢组织卵母细胞体外成熟。卵巢组织冷冻保存后，共获得5724个未成熟卵母细胞。约33.84%的未成熟卵母细胞通过体外成熟成功成熟，冷冻保存为卵母细胞或受精为胚胎，随后储存以备将来使用。
我们的综述提出了卵巢组织卵母细胞体外成熟在增加成熟卵母细胞数量方面的潜在应用。体外成熟后卵母细胞成熟率的可接受改善表明，改善卵母细胞结局是癌症女性保留生育能力的极好的成本效益策略。
